<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365400</url>
  </required_header>
  <id_info>
    <org_study_id>DS102A-07-CV1</org_study_id>
    <nct_id>NCT04365400</nct_id>
  </id_info>
  <brief_title>TRIgyceride And Glucose Control With Epeleuton in Metabolic Syndrome Patients</brief_title>
  <acronym>TRIAGE</acronym>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Dose Finding Phase IIb Study to Assess the Efficacy and Safety of Orally Administered Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afimmune</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of orally administered Epeleuton capsules versus placebo,&#xD;
      in the treatment of adult patients with hypertriglyceridemia and type 2 diabetes&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2020</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in triglycerides from baseline to week 16</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent change in triglycerides from baseline to week 16</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HbA1c from baseline to week 26</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change in HbA1c from baseline to week 26</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in triglycerides from baseline to weeks 4, 8, 12, 20 and 26</measure>
    <time_frame>26 weeks</time_frame>
    <description>Percent change in triglycerides from baseline to weeks 4, 8, 12, 20 and 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline to weeks 4, 8, 12, 16 and 20</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in HbA1c from baseline to weeks 4, 8, 12, 16 and 20</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>DS102 2000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive 1000mg DS102 capsules twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS102 4000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive 2000mg DS102 capsules twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group will receive placebo capsules twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS102</intervention_name>
    <description>DS102 capsules</description>
    <arm_group_label>DS102 2000mg</arm_group_label>
    <arm_group_label>DS102 4000mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients diagnosed with type 2 diabetes mellitus at least 90 days prior to the first&#xD;
        screening visit. Patients with a HbA1C (glycosylated haemoglobin) between 7- 10%&#xD;
        (53-86mmol/mol) Patients with a fasting triglyceride level ≥200 mg/dL and &lt;750mg/dL at both&#xD;
        screening visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who have a history of intolerance or hypersensitivity to any substance in&#xD;
        epeleuton capsules, placebo capsules or statins.&#xD;
&#xD;
        Patients with active severe liver disease defined as any of the following;&#xD;
&#xD;
          1. cirrhosis,&#xD;
&#xD;
          2. active hepatitis,&#xD;
&#xD;
          3. biliary obstruction with hyperbilirubinemia (total bilirubin &gt;2 times the upper limit&#xD;
             of normal) and AST or ALT &gt;3 times the upper limit of normal.&#xD;
&#xD;
        Patients with a history of malignancies within the past 5 years other than curatively&#xD;
        treated non-melanoma skin cancer (basal cell or squamous cell carcinomas).&#xD;
&#xD;
        Patients who have been treated with any investigational product within 60 days prior to&#xD;
        visit 1, or 5 half-lives (whichever is longer). Patients cannot participate in any other&#xD;
        investigational medication or medical device trial while participating in this study.&#xD;
&#xD;
        Patients who have been treated with any medication for diabetes or obesity in the four&#xD;
        weeks before the baseline visit, except for metformin, sulfonylureas, DPP-4 inhibitors,&#xD;
        SGLT2 inhibitors and short-term insulin treatment for acute illness for a total of below or&#xD;
        equal to 14 days.&#xD;
&#xD;
        Patients who have a family or personal history of multiple endocrine neoplasia type 2 or&#xD;
        medullary thyroid carcinomas.&#xD;
&#xD;
        Patients who have a history of acute or chronic pancreatitis. Patients who have a history&#xD;
        of major surgical procedures involving the stomach potentially affecting absorption of&#xD;
        investigational medicinal product (e.g. subtotal and total gastrectomy, sleeve gastrectomy,&#xD;
        gastric bypass surgery) Patients who have planned major surgical procedures, coronary&#xD;
        intervention (such as stent placement or heart bypass), carotid or peripheral&#xD;
        revascularisation. Patients who have a history of myocardial infarction, stroke, coronary&#xD;
        revascularisation or hospitalisation for unstable angina in the 3 months prior to&#xD;
        screening.&#xD;
&#xD;
        Patients who have a history of diabetic ketoacidosis. Patients with significant systemic or&#xD;
        major illnesses that, in the opinion of the Investigator, would preclude or interfere with&#xD;
        treatment with Epeleuton, adequate follow up and/or compliance with the protocol.Patients&#xD;
        who are pregnant, planning pregnancy, breastfeeding and/or are unwilling to use adequate&#xD;
        contraception (as specified in Inclusion Criterion 9) during the trial.&#xD;
&#xD;
        Patients who have previously entered into the study. Patients, in the opinion of the&#xD;
        Investigator, not suitable to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kirsty Kelly</last_name>
    <phone>+3532946380</phone>
    <email>k.kelly@afimmune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Moayed Hamza, MD</last_name>
    <phone>+3532946380</phone>
    <email>m.hamza@afimmune.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>US Site 2</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>US Site 1</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Germany Site 2</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Germany Site 7</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Germany Site 3</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Germany Site 1</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Germany Site 4</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Germany Site 5</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Germany Site 6</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Israel Site 9</name>
      <address>
        <city>Herzliya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Israel Site 1</name>
      <address>
        <city>H̱olon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Israel Site 5</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Israel Site 6</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Israel Site 4</name>
      <address>
        <city>Nahariya</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Israel Site 7</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Israel Site 8</name>
      <address>
        <city>Sakhnīn</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Israel Site 2</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Israel Site 3</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Latvia Site 4</name>
      <address>
        <city>Ogre</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Latvia Site 1</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Latvia Site 2</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Latvia Site 3</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Switzerland Site 3</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Switzerland Site 4</name>
      <address>
        <city>Luzern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Switzerland Site 2</name>
      <address>
        <city>Olten</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Switzerland Site 1</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Switzerland Site 5</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

